Compare Home Depot Inc (HD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Summit Therapeutics Inc — how do they compare? Home Depot Inc trades at $291.01 (market cap $294.79B), while Summit Therapeutics Inc trades at $17.09 (market cap $13.71B). The key difference: Home Depot Inc is far larger — about 21.5× Summit Therapeutics Inc's market cap, and Home Depot Inc pays a 3.15% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Summit Therapeutics Inc for 16 Days on average.
| HD | SMMT | |
|---|---|---|
Market Cap | $294.79B | $13.71B |
Volume | 8,693,917 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $26.38 |
52-Week Low | $281.15 | $12.43 |
Typical Hold Time | 139 Days | 16 Days |
Enterprise Value | $355.27B | $13.04B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $285.77, down 0.32% on the day, with a bearish technical signal despite strong analyst support. The stock shows consistent earnings beats in recent quarters with Q2 2026 EPS of $4.92 exceeding expectations. Revenue reached $159.51B in 2025, though profit margins have declined from 10.87% in 2022 to 9.28% currently. Institutional activity shows mixed positioning with some funds increasing while others reducing holdings.
The stock presents a compelling value opportunity with a consensus price target of $379.93 representing 33% upside potential. However, weakening profit margins, rising mortgage rates impacting housing demand, and bearish technical indicators create near-term headwinds. Long-term prospects remain supported by professional segment growth and housing market tailwinds.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
